Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J.

Nat Struct Biol. 2002 Apr;9(4):268-72.

PMID:
11896401
2.

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.

Cirillo PF, Pargellis C, Regan J.

Curr Top Med Chem. 2002 Sep;2(9):1021-35. Review. Erratum in: Curr Top Med Chem. 2002 Dec;2(12):following 1394..

PMID:
12171569
3.
4.

Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors.

Bolós J.

Mini Rev Med Chem. 2005 Sep;5(9):857-68. Review.

PMID:
16178727
5.

p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.

Adams JL, Badger AM, Kumar S, Lee JC.

Prog Med Chem. 2001;38:1-60. Review. No abstract available.

PMID:
11774793
6.

Unique MAP Kinase binding sites.

Akella R, Moon TM, Goldsmith EJ.

Biochim Biophys Acta. 2008 Jan;1784(1):48-55. Epub 2007 Nov 19. Review.

7.

Protein tyrosine kinases: structure, substrate specificity, and drug discovery.

al-Obeidi FA, Wu JJ, Lam KS.

Biopolymers. 1998;47(3):197-223. Review.

PMID:
9817025
8.

[Theoretical basis and practical importance of enzyme inhibition].

Schneider F.

Acta Histochem Suppl. 1977;Suppl 18:65-74. Review. German. No abstract available.

PMID:
45637
9.

Design strategies to address kinetics of drug binding and residence time.

Cusack KP, Wang Y, Hoemann MZ, Marjanovic J, Heym RG, Vasudevan A.

Bioorg Med Chem Lett. 2015;25(10):2019-27. doi: 10.1016/j.bmcl.2015.02.027. Epub 2015 Mar 5. Review.

PMID:
25782745

Supplemental Content

Support Center